These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24778081)

  • 41. Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.
    Ding S; Liu N; Zhao H; Jiang G; Zhang X; Wang E
    Tumour Biol; 2016 Aug; 37(8):10917-22. PubMed ID: 26886284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
    V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
    Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ALK in Mesothelioma: To FISH or Not to FISH?
    Cornelissen R; Dubbink HJ; von der Thüsen JH
    J Thorac Oncol; 2020 Oct; 15(10):e168-e169. PubMed ID: 32981606
    [No Abstract]   [Full Text] [Related]  

  • 44. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
    Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An activating ALK gene mutation in ALK IHC-positive/FISH-negative nonsmall-cell lung cancer.
    Togashi Y; Mizuuchi H; Kobayashi Y; Hayashi H; Terashima M; Sakai K; Banno E; Mizukami T; Nakamura Y; de Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
    Ann Oncol; 2015 Aug; 26(8):1800-1. PubMed ID: 26002608
    [No Abstract]   [Full Text] [Related]  

  • 46. Detection of ALK protein expression in lung squamous cell carcinomas by immunohistochemistry.
    Wang J; Shen Q; Shi Q; Yu B; Wang X; Cheng K; Lu G; Zhou X
    J Exp Clin Cancer Res; 2014 Dec; 33(1):109. PubMed ID: 25527865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.
    Sim J; Kim H; Hyeon J; Choi Y; Han J
    J Korean Med Sci; 2018 Apr; 33(15):e123. PubMed ID: 29629521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
    Lei YY; Yang JJ; Zhang XC; Zhong WZ; Zhou Q; Tu HY; Tian HX; Guo WB; Yang LL; Yan HH; Chen HJ; Xie Z; Su J; Han JF; Wu YL
    Clin Lung Cancer; 2016 May; 17(3):223-31. PubMed ID: 26454342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.
    Martin V; Bernasconi B; Merlo E; Balzarini P; Vermi W; Riva A; Chiaravalli AM; Frattini M; Sahnane N; Facchetti F; Mazzucchelli L; Sessa F; Tibiletti MG
    J Thorac Oncol; 2015 Apr; 10(4):595-602. PubMed ID: 25514802
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement.
    Kim H; Park E; Kim YJ; Chung JH
    Virchows Arch; 2013 May; 462(5):597-9. PubMed ID: 23605565
    [No Abstract]   [Full Text] [Related]  

  • 54. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
    Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
    Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inflammatory myofibroblastic tumor of the lung in children: anaplastic lymphoma kinase (ALK) expression and clinico-pathological correlation.
    Siminovich M; Galluzzo L; López J; Lubieniecki F; de Dávila MT
    Pediatr Dev Pathol; 2012; 15(3):179-86. PubMed ID: 22280150
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches.
    Demidova I; Grinevich V; Avdalian A; Imyanitov E; Gikalo M; Savelov N; Novikova I; Samuilenkova O; Tiurin V; Ulianova E; Tsimafeyeu I; Tjulandin S
    Lung Cancer; 2017 Jan; 103():17-23. PubMed ID: 28024691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.